NCT05721326View on ClinicalTrials.gov

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

NAEnrolling by invitationINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Genetic Predisposition to DiseaseBreast Cancer FemaleOvarian CancerHereditary Breast and Ovarian CancerHereditary Cancer SyndromeHereditary DiseasesGene Mutation-Related Cancer
Interventions
OTHER

Sequential EHR Communications

The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER